EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma

Hyery Kim, Hee Mang Yoon, Eun Key Kim, Young Shin Ra, Hyo-Won Kim, Mi-Sun Yum, Min-Jee Kim, Jae Suk Baek, Yu Sub Sung, Sang Min Lee, Hyeong-Seok Lim, Byung Joo Lee und 11 weitere

Neuro-Oncology · 05.12.2024 · 26 (12) · 2352-2363

DOI: 10.1093/neuonc/noae121 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 08.07.2024. Verfasst von Hyery Kim und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibroma, Plexiform, Benzimidazoles. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare, Republic of Korea, National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The MEK inhibitor, selumetinib, reduces plexiform neurofibroma (PN) in pediatric patients with neurofibromatosis type 1 (NF1). Its safety and efficacy in adults with PN and effectiveness in other NF1 manifestations (eg, neurocognitive function, growth reduction, and café-au-lait spots) are unknown.

Methods

This open-label, phase II trial enrolled 90 pediatric or adult NF1 patients with inoperable, symptomatic, or potentially morbid, measurable PN (≥3 cm). Selumetinib was administered at doses of 20 or 25 mg/m2 or 50 mg q 12 hours for 2 years. Pharmacokinetics, PN volume, growth parameters, neurocognitive function, café-au-lait spots, and quality of life (QoL) were evaluated.

Results

Fifty-nine children and 30 adults (median age, 16 years; range, 3–47) received an average of 22 ± 5 (4–26) cycles of selumetinib. Eighty-eight (98.9%) out of 89 per-protocol patients showed volume reduction in the target PN (median, 40.8%; 4.2%–92.2%), and 81 (91%) patients showed partial response (≥20% volume reduction). The response lasted until cycle 26. Scores of neurocognitive functions (verbal comprehension, perceptual reasoning, processing speed, and full-scale IQ) significantly improved in both pediatric and adult patients (P < .05). Prepubertal patients showed increases in height score and growth velocity (P < .05). Café-au-lait spot intensity decreased significantly (P < .05). Improvements in QoL and pain scores were observed in both children and adults. All adverse events were CTCAE grade 1 or 2 and were successfully managed without drug discontinuation.

Conclusions

Selumetinib decreases PN volume in the majority of pediatric and adult NF1 patients while also showing efficacy in nonmalignant diverse NF1 manifestations. Trial Registration Cris.nih.go.kr Identifier (KCT0003700).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Neurofibroma, PlexiformBenzimidazolesHumansChildAdolescentMaleFemaleAdultYoung AdultChild, PreschoolMiddle AgedQuality of LifeFollow-Up StudiesProtein Kinase InhibitorsPrognosis

Stichwörter der Autor:innen

Café-au-Lait spotsmitogen-activated protein kinase kinasesneurofibromaneurofibromatosis 1plexiform

Substanzen

AZD 6244BenzimidazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Radiology and Research Institute of Radiology, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Plastic Surgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Neurosurgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Psychiatry, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Beom Hee Lee

Förderung

  • Ministry of Health and Welfare, Republic of Korea
  • National Research Foundation

Zitieren

APA

Kim, H., Yoon, H. M., Kim, E. K., Ra, Y. S., Kim, H. W., Yum, M. S., Kim, M. J., Baek, J. S., Sung, Y. S., Lee, S. M., Lim, H. S., Lee, B. J., Lim, H. T., Kim, D., Yoon, J., Bae, H., Hwang, S., Choi, Y. H., Kim, K. A., …, & Lee, B. H. (2024). Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro-Oncology, 26(12), 2352-2363. https://doi.org/10.1093/neuonc/noae121

Vancouver

Kim H, Yoon HM, Kim EK, Ra YS, Kim HW, Yum MS, et al. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro-Oncology. 2024;26(12):2352-2363. doi:10.1093/neuonc/noae121

BibTeX
@article{Kim2024,
  author = {Kim, Hyery and Yoon, Hee Mang and Kim, Eun Key and Ra, Young Shin and Kim, Hyo-Won and Yum, Mi-Sun and Kim, Min-Jee and Baek, Jae Suk and Sung, Yu Sub and Lee, Sang Min and Lim, Hyeong-Seok and Lee, Byung Joo and Lim, Hyun Taek and Kim, Dohyung and Yoon, Jihee and Bae, Hyunwoo and Hwang, Soojin and Choi, Yun-Ha and Kim, Kyung Ah and Choi, In Hee and Lee, Seung Won and Park, Su-Jung and Lee, Beom Hee},
  title = {Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {12},
  pages = {2352--2363},
  doi = {10.1093/neuonc/noae121}
}
Kostenlos starten →